BRCA1 and non-small cell lung carcinoma: A low expression of receptor-associated protein 80 (RAP80) was found to have a positive impact on the survival of NSCLC patients, and both BRCA1 and RAP80 had low expression levels in patients, showing an increased benefit from platinum therapy [32,33].